1	Sat	fety of Repeated Low-Level Red-Light Therapy for Myopia: A Systematic
2	Re	view
3		
4	Ru	nning Title: Safety of repeated low-level red-light therapy
5		
6	Au	thors
7	Ya	nping Chen, MD <sup>1</sup> *, Shida Chen, MD, PhD <sup>1</sup> *, Ruilin Xiong, MD, PhD <sup>1</sup> *, Shaopeng
8	Ya	ng, MD <sup>1</sup> , Riqian Liu, MD <sup>1</sup> , Ziyu Zhu, MBBS <sup>1</sup> , Kaidi Xiang, MD <sup>2,3</sup> , Nathan
9	Co	ngdon, MD, MPH <sup>1,4,5</sup> $\dagger$ , Wei Wang, MD, PhD <sup>1</sup> $\dagger$
10		
11	Af	filiations
12	1.	State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun
13		Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and
14		Visual Science, Guangdong Provincial Clinical Research Center for Ocular
15		Diseases, Guangzhou, Guangdong, China.
16	2.	Department of Clinical Research, Shanghai Eye Disease Prevention and
17		Treatment Center, Shanghai Eye Hospital, Shanghai Vision Health Center and
18		Shanghai Children Myopia Institute, Shanghai, China.
19	3.	Department of Ophthalmology, Shanghai General Hospital (Shanghai First
20		People's Hospital), Shanghai Jiao Tong University School of Medicine, Shanghai,
21		China; National Clinical Research Center for Eye Diseases; Shanghai Clinical
22		Research Center for Eye Diseases; Shanghai Key Clinical Specialty; Shanghai
23		Key Laboratory of Ocular Fundus Diseases; Shanghai Engineering Center for
24		Visual Science and Photomedicine; Shanghai Engineering Center for Precise
25		Diagnosis and Treatment of Eye Diseases, Shanghai Eye Research Institute,
26		Shanghai, China.
27	4.	Centre for Public Health, Queen's University Belfast, Belfast, United Kingdom.
28	5.	Orbis International, New York, New York, United States of America.
29	*C	o-first authors. †Co-corresponding authors.
30		

# 31 Corresponding Author

- 32 Wei Wang, MD PhD, Zhongshan Ophthalmic Center, State Key Laboratory of
- 33 Ophthalmology, Sun Yat-sen University, Guangzhou, China.
- 34 Email: wangwei@gzzoc.com | ORCID: https://orcid.org/0000-0002-5273-3332
- 35
- 36 Nathan Congdon, MD, MPH, Zhongshan Ophthalmic Center, State Key Laboratory of
- 37 Ophthalmology, Sun Yat-sen University, Guangzhou, China; Centre for Public Health,
- 38 Queen's University Belfast, Belfast, United Kingdom; Orbis International, New York,
- 39 New York, United States of America.
- 40 Email: ncongdon1@gmail.com | ORCID: https://orcid.org/0000-0001-9866-3416
- 41

### 42 Financial Support

- 43 This research was supported by the National Natural Science Foundation of China
- 44 (82371086). The sponsors or funding organizations had no roles in the design or
- 45 conduct of this research.
- 46

### 47 **Conflicts of Interests**

- 48 All authors declare no competing interests.
- 49
- 50 Word Count: [Abstract: 343 / Text: 3718]
- 51 **Tables: 4**
- 52 **Figures: 2**
- 53 Supplementary Tables: 3
- 54

### 55 Abbreviations and Acronyms:

- 56 RLRL = repeated low-level red-light; OCT = optical coherence tomography; CI =
- 57 confidence interval; IMI = International Myopia Institute; RCT = randomized
- 58 controlled trial; SER = spherical equivalent refraction; AL = axial length; NNH =
- number needed to harm; NNT = number needed to treat; SVS = single-vision
- 60 spectacles; BCVA = best-corrected visual acuity.

### 62 Abstract

63 **Topic:** Existing evidence for the safety of repeated low-level red-light (RLRL)

64 therapy for myopia control.

Clinical relevance: Recent trials show RLRL therapy is effective in the prevention
and control of myopia. Establishing its safety profile is necessary prior to widespread
clinical implementation.

68 Methods: We conducted a systematic review (International Prospective Register of 69 Systematic Reviews, CRD42024516676) of articles across seven databases from 70 inception through February 10, 2024, with keywords related to myopia and RLRL 71 therapy. Pooled safety outcomes and risk-to-benefit ratios were reported, and 72 incidence of side effects was compared with other anti-myopia interventions. Quality 73 appraisal was performed using the Cochrane Risk of Bias Tool. 74 **Results:** Among 689 screened articles, 20 studies (2.90%; eleven randomized 75 controlled trials, four non-randomized controlled trials, one post-trial study, one

<sup>76</sup> single-arm study, one retrospective study and two case reports of identical patient.;

median duration 9 months, longest 24 months) were analysed, encompassing 2,380

participants aged 3-18 years and 1,436 individuals undergoing RLRL therapy. Two

79 case reports described an identical patient with reversible decline in visual acuity and

80 optical coherence tomography (OCT) abnormalities, completely resolved 4 months

81 after treatment cessation. No cases of permanent vision loss were reported. Temporary

82 afterimage was the most common ocular symptom following treatment, resolving

83 within 6 minutes in reported studies. The number needed to harm outweighed the

number needed to treat by a ratio of 12.7-21.4 for a person with -3D to -8D myopia

treated with RLRL therapy. Incidence of side effects from RLRL was 0.088 per 100

patient-years (95% confidence interval [CI], 0.02-0.50), comparable to spectacles

designed for myopia reduction (0.22; 95% CI, 0.09-0.51; P=0.385), and significantly

lower than for low-dose atropine (7.32; 95% CI, 6.65-8.05; P<0.001), orthokeratology

89 (20.6; 95% CI, 16.7-25.0; P<0.001), other anti-myopia contact lens (19.3; 95% CI,

90 17.6-21.1; P<0.001).

91 **Conclusion:** No irreversible visual function loss or ocular structural damage was

- 92 identified with RLRL. Fundus photography and OCT before and during therapy,
- alongside home monitoring of visual acuity and duration of afterimages, are necessary
- 94 to identify side effects. Further adequately-powered studies of longer duration are
- 95 needed to evaluate long-term safety of RLRL.
- 96
- 97 Keywords: Refractive error, myopia prevention, repeated low-level red-light, safety,
- 98 risk-to-benefit
- 99

### 100 Introduction

Myopia is the most common ocular disorder of childhood and adolescence. Without effective intervention measures, it is estimated that approximately 50% of the global population will be affected by 2050.<sup>1</sup> The rising prevalence of myopia, along with earlier onset, increases the risk of high myopia, which may be associated with irreversible, sight-threatening complications such as myopic maculopathy, glaucoma and retinal detachment.<sup>2-4</sup> Therefore, prevention and control of myopia have become important public health challenges.

108

109 Repeated low-level red-light (RLRL) therapy, highlighted in the latest 2023 Digest of 110 the International Myopia Institute (IMI), has emerged as a novel approach to myopia prevention.<sup>5</sup> RLRL therapy involves locally irradiating the retina with low-level red 111 112 light (approximately 1600 lux). It falls under Group 1 of the ANSI Z80.36-2021 standard,<sup>6</sup> ensuring its safety for clinical ophthalmic applications. Unlike traditional 113 114 therapeutic lasers such as panretinal photocoagulation, which rely on thermal effects 115 generated through transpupillary energy ranging from 200-250 mW passing through 116 the pupil, RLRL uses a much lower energy level of 0.29 mW, avoiding any thermal 117 effects. Its therapeutic impact is postulated to rely on photobiomodulation (PBM) 118 secondary to the laser's energy, potentially leading to thickening of the choroidal layer.<sup>7</sup> 119

120

121 Growing trial evidence supports the effectiveness of RLRL therapy in reducing 122 myopia progression. The first multicenter randomized controlled trial (RCT) in China 123 demonstrated in 2019 that home-based RLRL therapy, administered for 3 minutes 124 twice daily for 5 days a week, significantly reduced axial elongation by 69.4% and refractive progression by 76.6% among school-aged children.<sup>8</sup> Subsequent clinical 125 trials have consistently confirmed these findings.<sup>9-11</sup> Recently, a meta-analysis 126 127 incorporating 13 studies comprising 8 RCTs, 3 non-randomized controlled trials and 2 cohort studies, and involving a total of 1857 children and adolescents, confirmed the 128 efficacy of RLRL therapy.<sup>12</sup> Six-month weighted differences in spherical equivalent 129

refraction (SER) and axial length (AL) were 0.68 diopters (D) and 0.35 mm

131 respectively between the RLRL treatment group and controls. However, published

studies have predominantly focused on efficacy outcomes, with limited reporting of

the safety and side effects of RLRL therapy.

134

135 To address this important knowledge gap, we systematically reviewed the safety

136 profiles and risk-to-benefit ratio associated with RLRL treatment for myopia

137 prevention and control. The aim of this study is to provide insights to help both

138 clinicians and program designers optimize use of RLRL therapy, ensuring its safe and

139 effective integration into myopia management.

140

### 141 Methods

This review was registered prospectively on the International Prospective Register of
Systematic Reviews database (available from

144 https://www.crd.york.ac.uk/prospero/display\_record.php?ID=CRD42024516676) and

145 is reported in accordance with the Preferred Reporting Items for Systematic Reviews

and Meta-Analyses (PRISMA) statement.<sup>13</sup> All research adhered to the tenets of the

147 Declaration of Helsinki. Individual patient-level consent was not required, nor was148 ethical review.

149

### 150 Eligibility Criteria

151 We included clinical studies of RLRL therapy designed to prevent myopia or delay its 152 progression. Studies were selected according to the following criteria: (1) Participants 153 were younger than 18 years with myopia or premyopia; (2) RLRL therapy was used in 154 at least one arm or by all participants; (3) Reporting of at least 1 safety outcome, 155 including visual function, ocular structural assessment, or adverse events; (4) All 156 study types except literature reviews, in order to capture as many reported safety 157 profiles and side effects as possible. We excluded studies on non-human subjects, 158 those enrolling participants with secondary myopia, without safety data, and those 159 merely describing treatments combined with RLRL therapy or involving red light

160 flicker rather than continuous administration.

161

### 162 Search Strategy

163 A comprehensive search of the peer-reviewed literature was conducted across seven 164 databases, including PubMed, Embase, Web of Science, Cochrane Library, Scopus, 165 the Chinese databases China National Knowledge Infrastructure and VIP Information 166 Database, from their dates of inception through 10 February 2024. We used a 167 combination of key words related to myopia and RLRL therapy, imposing no 168 language restrictions. To ensure thorough coverage, we also scrutinized relevant 169 reviews and all references cited by eligible studies for additional pertinent 170 publications. The full search strategy is detailed in Table S1. 171 172 **Study Selection** 173 Citations retrieved from electronic databases were compiled into an EndNote library 174 by one author (Y.C.). After the removal of duplicates, two reviewers (Y.C., R.X.) 175 independently screened titles and abstracts to assess initial eligibility. Reviewers then 176 checked the full text for potentially eligible studies to determine their final inclusion 177 or exclusion. The primary reason for exclusion was documented at the full text 178 screening stage. Any discrepancies between reviewers were resolved through 179 discussion or by consulting a third researcher if necessary (W.W.). 180 181 **Data Collection and Risk of Bias Assessment** 182 Data were extracted independently by two reviewers (Y.C., R.X.) 183 and were entered into an Excel spreadsheet (version 2022, Microsoft Corporation, 184 Redmond, USA). For each included study, the extracted information consisted of 185 author's name, year of publication, study design, country or area, specification of the 186 red light device (device name, manufacturer, wavelength and power), treatment 187 regimen, sample size, follow-up duration, age, sex, baseline SER, baseline AL, safety 188 outcomes, and participation completion rate. For the safety outcomes, we documented 189 all safety data reported throughout the selected studies. Two reviewers (Y.C., S.Y.)

independently appraised articles for systematic bias using the Cochrane Risk of Bias
Tool.<sup>14</sup>

192

### 193 Data Synthesis and Analysis

194 Given the heterogeneous reporting of safety outcomes among the included studies, it was not feasible to conduct a pooled meta-analysis.<sup>15</sup> Instead, we performed a 195 risk-to-benefit analysis according to the model described by Bullimore to assess 196 197 whether the potential benefits of reducing myopia progression of 1D with RLRL therapy outweigh the potential risks associated with the treatment.<sup>16</sup> The revised 198 199 Bullimore's model is based on three assumptions: 1) Every patient undergoing myopia 200 control will use RLRL for a 5-year treatment period. Since there's lack of long-term 201 efficacy of RLRL therapy, the selection of five years facilitates the conservative 202 estimation of the effect of controlling myopia progression within 1D as per previous review.<sup>17</sup> 2) Serious adverse events, if they occur, may happen at a mean age of 12 203 years during this five-year treatment period.<sup>16</sup> 3) Based on the estimated mean life 204 205 expectancy of 77 years in China (https://data.who.int), any adverse event resulting in 206 immediate visual impairment will lead to visual impairment for a duration of 65 years. 207 The annual incidence rate of vision loss was calculated using the number of children 208 experiencing visual impairment from RLRL as the numerator and the estimated total 209 number of patient-years in reported clinical RLRL studies with safety outcomes as the 210 denominator. The absolute risk increase (ARI) of vision loss years was estimated by 211 multiplying the annual incidence of vision loss per 10,000 patients by the assumed 212 duration of visual impairment, which is 65 years. The number needed to harm (NNH) 213 was then calculated as the reciprocal of ARI. This metric indicates the number of 214 patients who need to be treated to induce one case of visual impairment.

215

According to Bullimore's model, the benefit of preventing visual impairment from blinding myopic related complications by 1D was regardless of the treatment. The average duration of visual impairment that a patient is likely to experience over their lifetime at myopia ranging from -3D to -8D was estimated. <sup>16</sup> For instance, a patient

220 with -3D myopia is expected to experience an average of 4.42 years of visual 221 impairment (mild visual impairment as US definition of 20/40) while a -4D person 222 will experience 5.25 years of visual impairment. Thus, the benefit of slowing myopia 223 progression by 1D is quantified by the difference in years of visual impairment, 224 amounting to a prevention of 0.84 years of visual impairment if myopia control 225 interventions in an individual potentially reaching -4D myopia result in achieving 226 only -3D. The values of years of visual impairment prevented by 1D reduction ranges 227 from 0.74 to 1.22 for -3D to -8D. The number needed to treat (NNT) was evaluated in 228 Bullimore's model to prevent 1-year (NNT range, 0.82-1.38) and 5-year (NNT range, 4.11-6.75) visual impairment.<sup>16</sup> Furtherly, we calculated the NNH/NNT ratio for 229 230 RLRL therapy in patients with myopia degrees ranging from -3D to -8D. 231 232 Additionally, we conducted a systematic comparison of the incidence of side effects 233 between RLRL therapy and other anti-myopia interventions. Our approach involved a 234 systematic search of all eligible peer-reviewed RCTs that included myopic or 235 premyopic participants younger than 18 years, had at least a one-year follow-up

236 period, and investigated interventions including low-dose atropine, orthokeratology,

237 other contact lenses, and spectacles. For spectacles, we included bifocal lens,

238 progressive addition spectacles, aspherical lenslets and peripheral defocus spectacles

- as spectacles designed for myopia reduction since their incidence rates of adverse
- 240 events were similar. Adverse events of other interventions were counted as the number
- 241 of events reported in published RCTs. The crude incidence of adverse events was

computed per 100 patient-years of intervention, with 95% confidence intervals (CIs)

calculated using the Wilson method.<sup>18, 19</sup> A two-sided p value <0.05 was defined as

statistically significant. All data analyses were performed using Stata (version 17.0,

245 StataCorp, College Station, Texas, USA).

246

247 **Results** 

# 248 Study Selection

Of the 689 references retrieved, 39 full-text articles (5.66%) were reviewed, and 20

studies (2.90%) were identified as eligible for systematic review (Figure 1). The

251 primary reason for exclusion during the full-text review process was the absence of

- 252 reported safety outcomes (n=14, 73.7%).<sup>7, 20-32</sup>
- 253

## 254 Characteristics of Included Studies

The 20 studies comprised eleven RCTs,<sup>8, 10, 11, 33-40</sup> four non-randomized controlled 255 trials,<sup>41-44</sup> one post-trial study,<sup>9</sup> one single-arm study,<sup>45</sup> one retrospective study<sup>46</sup> and 256 two case reports of identical patient.<sup>47, 48</sup> Fifteen studies evaluated the safety and 257 258 efficacy of RLRL therapy compared to controls, eleven with single-vision spectacles (SVS),<sup>8, 10, 33, 35-37, 39-43</sup> one with a sham device,<sup>11</sup> one with 0.01% atropine,<sup>34</sup> and one 259 with orthokeratology, SVS, and combination treatment of orthokeratology and 260 RLRL.<sup>44</sup> One study compared the safety and efficacy between RLRL devices with 261 different powers and SVS.<sup>38</sup> Two case reports described the identical individual case 262 with different details;<sup>47, 48</sup> thus we comprehensively reviewed the two reports but only 263 264 included as one participant in the systematic review. These studies included a total of 265 2,380 participants aged 3-18 years presenting at baseline with myopia (cycloplegic 266 SER -0.50 to -9.00D) or premyopia (cycloplegic SER -0.50 to +0.75D), among them 1,436 subjects undergoing RLRL therapy. The median follow-up duration was 9 267 months, with an interquartile range of 6-12 months, and a longest follow-up period of 268 269 24 months. All studies reported a participant completion rate of over 50%, were 270 conducted in China, and published between 2021 and 2024. (Table 1). The risk of bias 271 assessment is shown in Figure 2. 2.72

273 The specifications of RLRL therapy and treatment regimens across the included

- studies are summarized in Table S2. Four types of RLRL devices were utilized,
- including Eyerising (Jiangsu, China; n=14 studies; 650±10 nm, 2.00±0.50 mW),<sup>8-11, 33,</sup>
- 276 <sup>34, 40-42, 44-48</sup> LD-A (Jilin, China; n=2 studies; 635 nm, 0.35±0.02 mW),<sup>35, 37</sup> YF020A
- 277 (Hunan, China; n=3 studies; 650 nm, no specified power),<sup>36, 39, 43</sup> and sky-n1201
- 278 (Beijing, China; n=1 study; 650 nm, with variable outputs of 0.37±0.02 mW, 0.60±0.2
- mW, and 1.20 mW).<sup>38</sup> All studies adhered to a uniform daily RLRL treatment protocol,

- consisting of two daily 3-minute sessions, with a minimum interval of 4 hours
- between sessions. Six studies implemented a 5-day per week regimen,<sup>8-10, 41, 43, 46</sup>
- while the remaining 14 studies provided treatment 7 days per week.<sup>11, 33-40, 42, 44, 45, 47, 48</sup>
- 283

# 284 Safety Profiles of RLRL Therapy

285 **Table 2** presents the safety outcomes reported among participants undergoing RLRL 286 therapy. In these studies, visual function was assessed using best-corrected visual 287 acuity (BCVA) or multifocal electroretinogram, while ocular structures were 288 evaluated with optical coherence tomography (OCT), fundus photography, or 289 slit-lamp microscopy. Among 529 children assessed for visual function, 528 (99.8%) 290 either maintained a BCVA of  $\geq 20/25$  or experienced no decline at follow-up visits 291 compared to baseline. OCT identified no structural damage in 624 (99.8%) of the 625 292 participants with such data.

293

294 Two case reports described the same twelve-year-old girl who experienced a two-line decline in binocular BCVA after five months of RLRL therapy.<sup>47, 48</sup> The child was 295 296 highly myopic prior to initiating RLRL, with SER of -6.75D in the right eye and 297 -6.25D in the left eye, and BCVA of 20/25 at the point of initiation. Due to repeated 298 inflammation from orthokeratology, the subject had been switched to RLRL for 299 managing myopia. After three months of RLRL treatment, the BCVA improved to 300 20/20. After five months for RLRL treatment, the child showed the binocular BCVA 301 decrease from 20/20 to 20/30 with prolonged afterimages occasionally exceeding 8 302 minutes. Multifocal electroretinogram indicated moderately and mildly decreased 303 response in the macula and paramacular respectively. OCT images showed bilateral 304 disruption of the foveal ellipsoid zone and discontinuity of the interdigitation zone. 305 Fundus photographs revealed bilaterally darkened foveae with a hypoautofluorescent 306 plaque in autofluorescence images. The bilateral outer retinal damage showed partial 307 recovery, with an improvement in binocular BCVA to 20/25, three months after 308 discontinuation of RLRL therapy. Complete recovery of bilateral outer retinal damage 309 was observed four months after discontinuing RLRL therapy.

311 Nineteen studies reported on ocular adverse events. In one study with 20 participants 312 treated with RLRL, afterimages lasting a mean of 3.2±1.2 minutes were documented without any objective ocular abnormalities.<sup>37</sup> One trial reported afterimage as the 313 314 most common phenomenon post light therapy, which can be alleviated by a short period of eve-closing and rest.<sup>41</sup> Another study demonstrated no afterimages longer 315 than 6 minutes after 1-year RLRL treatment within 126 premyopic children.<sup>10</sup> One 316 317 individual experienced dizziness following the red-light therapy; however, this 318 symptom resolved within a few minutes and persisted during the immediate post-treatment period for only a few days.<sup>34</sup> Aside from the aforementioned case 319 report,  $^{47, 48}$  no other included participants experienced vision loss of  $\geq 2$  lines, scotoma 320 321 or treatment-related adverse events post-therapy.

322

## 323 Risk-to-benefit Analysis

324 The sole event of temporary vision loss described in the case reports is considered as the numerator,<sup>47, 48</sup> and the denominator is a conservative estimate of the total number 325 326 of participants in reported clinical RLRL studies with safety outcomes. The annual 327 incidence of vision loss from RLRL therapy was estimated as 8.77 per 10,000 328 patient-years. Table 3 shows the NNH and NNH/NNT estimates for 1 year and 5 329 years visual impairment associated with RLRL based on Bullimore's model. A total of 330 17.5 individuals have to implement RLRL therapy for 5 years to result in 1-year of 331 visual impairment, while 87.7 patients have to use it to result in 5-year of visual 332 impairment.

333

From Bullimore's assessment, controlling myopia by 1D prevents between 0.74 and
1.22 years of visual impairment due to myopic complications across myopia levels of

- -3D to -8D.<sup>16</sup> This benefit outweighs the risk of visual impairment years from RLRL
- treatment, which is 570 per 10,000 patients, or 0.057 year per patient. On the other
- hand, the NNH outweighs the NNT by a ratio of 12.7-21.4 for a person with -3D to
- -8D myopia treated with RLRL therapy.

#### 340

### 341 Comparison with Other Interventions

We further compared the incidence rates of ocular adverse events between RLRL and other myopia interventions. The characteristics and adverse events of other treatments reported in RCTs lasting at least 1 year are displayed in **Table S3**. The side effect incidence of RLRL therapy is 0.088 per 100 patient-years (95% confidence interval [CI], 0.02-0.50), which is comparable to spectacles designed for myopia reduction (0.22 per 100 patient-years; 95% CI, 0.09-0.51; P=0.385),<sup>49-59</sup> and significantly lower

- than for low-dose atropine (7.32 per 100 patient-years; 95% CI, 6.65-8.05;
- <sup>349</sup> P<0.001),<sup>60-78</sup> orthokeratology (20.6 per 100 patient-years; 95% CI, 16.7-25.0;
- P<0.001)<sup>77, 79-84</sup> and other anti-myopia contact lens (19.3 per 100 patient-years; 95%
- 351 CI, 17.6-21.1; P<0.001)<sup>85-90</sup> (**Table 4**).
- 352

### 353 Discussion

354 The results of the systematic review indicated that no visual function loss or ocular 355 structural change with irreversible damage was identified with RLRL therapy. An 356 afterimage was the most common ocular symptom following treatment, with a 357 resolution time of less than 6 minutes reported in two clinical trials. This phenomenon, 358 induced by prior adaptation to a visual stimulus, is believed to be due to the natural 359 bleaching of photochemical pigments or neural adaptation in the retina. Participants 360 with an afterimage duration exceeding 6 minutes were considered clinically too sensitive to the light stimulus.<sup>10,91</sup> Among dozens of published studies, only two 361 reported on a single case of a reversible decline in visual function and discontinuity of 362 363 the foveal ellipsoid and interdigitation zones in an identical girl, with complete 364 recovery after four months of treatment cessation. A risk-to-benefit analysis 365 emphasized that the benefit of reducing visual impairment outweighed the potential 366 risks associated with RLRL treatment. The incidence rate of side effects from RLRL 367 therapy was comparable to that of spectacles wearing, and was lower than that of 368 other therapies.

369

370 Of note, two case reports, both describing on complications of the same child 371 following RLRL therapy offers valuable clinical data and serves as a reference point for RLRL's clinical application.<sup>47,48</sup> Given the rarity of this adverse event, it might be 372 373 secondary to specific individual differences, where the patient may be especially 374 responsive to light therapy. Such individual variability may render the retina more 375 sensitive to light and prone to phototoxicity. It is important to note that the patient was 376 highly myopic, a condition that often involves inherent issues with the retinal 377 structure of the fundus. From the addition information provided by the authors of one case report.<sup>48</sup> this child experienced significant myopia regression (cycloplegic SER 378 379 from -6.75D at baseline to -4.50D after 1 month in the right eye; from -6.25D at 380 baseline to -4.50D after 1 month in the left eye) following RLRL treatment. The dark 381 choroid shown in the OCT image post RLRL has been suggested in a non 382 peer-reviewed letter to the editor regarding the case written by experts in inherited 383 retinal disease to represent Stargardt's disease 384 (https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2805391). 385 386 Although the incidence of such adverse events is extremely low, identifying such 387 super-responders to RLRL therapy is still important. From this case, possible

388 characteristics of super-responders include a significant treatment effect, a marked 389 SER regression or AL shortening and an afterimage duration exceeding 6 minutes in 390 response to light exposure. It is crucial for clinicians and parents to closely monitor 391 subjects with these characteristics, as any decrease in visual acuity while wearing 392 glasses may suggest the development of such complications, which can then be 393 further detected and characterized through OCT examination. Importantly, these 394 complications are reversible as after stopping treatment for 4 months, the visual 395 function and ocular structures changes returned to normal. Meticulous supervision is 396 thus necessary throughout the treatment process to ensure safe implementation of 397 RLRL. Appropriate actions include documentation of the retina through fundus 398 photography and OCT before starting treatment and at each routine examination, tracking visual acuity, and recording the duration of any afterimages.<sup>92</sup> 399

401 A comprehensive risk-to-benefit assessment of myopia treatments should consider 402 various factors, including the intervention effectiveness in slowing myopia 403 progression, the risk of myopia-related visual impairment, the degree of myopia 404 treated, and the specific risks associated with each intervention. From this 405 risk-to-benefit analysis, the risk of vision loss associated with RLRL treatment is seen 406 to be counterbalanced by its benefits in preventing myopia-related visual impairment 407 with a NNH/NNT ratio of 12.7 to 21.4. Previous studies have reported a NNH/NNT ratio ranging from 5.43 for -3D to 9.15 for -8D for overnight contact lens wearing.<sup>16</sup>, 408 93 409

410

400

411 Additionally, nearly all interventions for myopia control are associated with some 412 side effects and complications. Our systematic review summarized RCTs with at least 413 one year of follow-up reporting the incidence of side effects from available 414 anti-myopia interventions. Our findings indicate that the incidence of adverse events 415 associated with orthokeratology is 20.6 per 100 patient-years, while it was 19.3 per 416 100 patient-years for other contact lens. Complications linked to contact lens usage 417 included ocular noninfectious inflammatory events and sight-threatening microbial keratitis.<sup>90, 94-96</sup> A retrospective study authorized and approved by the US FDA 418 estimated the incidence of microbial keratitis from orthokeratology in children to be 419 14 per 10,000 patient-years (95% CI, 1.7-50.4 per 10,000 patient-years).<sup>97</sup> Atropine, 420 421 even at low concentrations of 0.01%, may lead to pupil dilation and loss of accommodation, with photophobia, reduced near vision, and allergic conjunctivitis 422 being commonly reported ocular side effects.<sup>98, 99</sup> Spectacles in comparison are a 423 more well-tolerated method for correcting and controlling myopia; however, they are 424 associated with a low risk of falls and bicycle collisions.<sup>51, 100</sup> In this review, RLRL 425 therapy had a comparable incidence of side effects with spectacles. 426 427

This systematic review provides the first comprehensive evidence on the safety profile and the risk-to-benefit ratio of RLRL therapy for myopia control. However, the results

430 should be interpreted within the context of several limitations. Firstly, most studies 431 lasted for 12 months, with only 11 children undergoing 24-month treatment in one 432 post-trial study included thereby limiting long-term evidence. There is a need for 433 further large-scale studies to thoroughly assess the long-term safety of RLRL therapy 434 in children and adolescents. Secondly, visual function in the included studies was 435 primarily evaluated using visual acuity, which could be influenced by subjective 436 factors. Objective assessments, such as multifocal electroretinography or 437 microperimetry, are necessary to provide more comprehensive safety evidence for 438 RLRL therapy. Thirdly, the methodology for reporting adverse events varied widely 439 across studies. Some studies documented the number of patients experiencing side 440 effects, whereas others detailed the number of adverse events. Fourthly, the accuracy of Bullimore's model is dependent on the validity of its assumptions.<sup>16</sup> It presumses 441 442 that the risk of vision loss from RLRL therapy is independent of refractive error. The 443 model also assumes a fixed treatment effect with myopia control. Fifthly, quality 444 appraisal was employed exclusively for the included RCTs, as the Cochrane Risk of 445 Bias Tool is not designed for use with non-randomized controlled trial, post-trial study, 446 retrospective study, single-arm study or case report. Finally, eleven of the twenty 447 studies were RCTs, which were conducted under strict surveillance. Such studies may 448 not accurately reflect real-world vision care, therefore more real-world studies are 449 needed to better understand long-term safety of RLRL in a greater variety of settings. 450

### 451 **Conclusion**

452 In conclusion, no irreversible visual function loss or ocular structural damage 453 associated with RLRL therapy was identified in this review. Meticulous supervision is 454 crucial throughout the entire treatment process by clinicians and parents, including 455 documenting the status of retina through fundus photography and OCT before 456 initiating RLRL therapy and at each routine examination, as well as tracking visual 457 acuity and the duration of any afterimages at home. Screening for and early 458 identification of rare super-responders is also important to avoid potential light injury. 459 Future larger and longer-term real-world studies are needed to better understand the

460 long-term safety of RLRL.

461

# 462 Acknowledgment

- 463 The authors thank the Hainan Province Clinical Medical Center, the National Natural
- 464 Science Foundation of China (82371086) for their support.

465

## 466 Author Contributions:

- 467 Prof. Wang had full access to all the data in the study and took responsibility for the
- integrity of the data and the accuracy of the data analysis.
- 469 Study concept and design: Chen, Congdon, Wang.
- 470 Data collection: Chen, Chen, Xiong, Yang, Wang.
- 471 Analysis and interpretation of data: Chen, Wang.
- 472 Drafting of the manuscript: Chen, Congdon, Wang.
- 473 Critical revision of the manuscript for important intellectual content: All authors.
- 474 Statistical analysis: Chen, Wang.
- 475 Obtained funding: Wang.
- 476 Administrative, technical, or material support: Congdon, Wang.
- 477 Overall supervision: Wang.

### 478 **References:**

- 1. Holden BA, Fricke TR, Wilson DA, et al. Global Prevalence of Myopia and High
- 480 Myopia and Temporal Trends from 2000 through 2050. Ophthalmology
- 481 2016;123(5):1036-42.
- 482 2. Bullimore MA, Brennan NA. Myopia Control: Why Each Diopter Matters.
- 483 Optom Vis Sci 2019;96(6):463-5.
- 484 3. Ikuno Y. Overview of the Complications of High Myopia. Retina
- 485 2017;37(12):2347-51.
- 486 4. Mitchell P, Hourihan F, Sandbach J, Jin Wang J. The relationship between
- 487 glaucoma and myopia. Ophthalmology 1999;106(10):2010-5.
- 488 5. Sankaridurg P, Berntsen DA, Bullimore MA, et al. IMI 2023 Digest. Invest
- 489 Ophthalmol Vis Sci 2023;64(6):7.
- 490 6. ANSI. American National Standard for Safe Use of Lasers (ANSI Z80.36). The
- 491 Laser Institute of America. ANSI Z80.36-2021.
- 492 7. Xiong R, Zhu Z, Jiang Y, et al. Longitudinal Changes and Predictive Value of
- 493 Choroidal Thickness for Myopia Control after Repeated Low-Level Red-Light
- 494 Therapy. Ophthalmology 2023;130(3):286-96.
- 495 8. Jiang Y, Zhu Z, Tan X, et al. Effect of Repeated Low-Level Red-Light Therapy
- 496 for Myopia Control in Children: A Multicenter Randomized Controlled Trial.
- 497 Ophthalmology 2022;129(5):509-19.
- 498 9. Xiong R, Zhu Z, Jiang Y, et al. Sustained and rebound effect of repeated low-level
- 499 red-light therapy on myopia control: A 2-year post-trial follow-up study. Clin Exp
- 500 Ophthalmol 2022;50(9):1013-24.
- 10. He X, Wang J, Zhu Z, et al. Effect of Repeated Low-level Red Light on Myopia
- 502 Prevention Among Children in China With Premyopia: A Randomized Clinical Trial.
- 503 JAMA Netw Open 2023;6(4):e239612.
- 11. Dong J, Zhu Z, Xu H, He M. Myopia Control Effect of Repeated Low-Level
- 505 Red-Light Therapy in Chinese Children: A Randomized, Double-Blind, Controlled
- 506 Clinical Trial. Ophthalmology 2023;130(2):198-204.
- 507 12. Tang J, Liao Y, Yan N, et al. Efficacy of Repeated Low-Level Red-Light Therapy

- 508 for Slowing the Progression of Childhood Myopia: A Systematic Review and
- 509 Meta-analysis. Am J Ophthalmol 2023;252:153-63.
- 510 13. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an
- 511 updated guideline for reporting systematic reviews. BMJ 2021;372:n71.
- 512 14. Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool
- for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.
- 514 15. Gilbert CE, Lepvrier-Chomette N. Gender Inequalities in Surgery for Bilateral
- 515 Cataract among Children in Low-Income Countries: A Systematic Review.
- 516 Ophthalmology 2016;123(6):1245-51.
- 517 16. Bullimore MA, Ritchey ER, Shah S, et al. The Risks and Benefits of Myopia
- 518 Control. Ophthalmology 2021;128(11):1561-79.
- 519 17. Brennan NA, Toubouti YM, Cheng X, Bullimore MA. Efficacy in myopia control.
- 520 Prog Retin Eye Res 2021;83:100923.
- 521 18. Agresti A, Coull B. Approximate Is Better than "Exact" for Interval Estimation of
- 522 Binomial Proportions. The American Statistician 1998;52(2):119-26.
- 523 19. Wilson E. Probable Inference, the Law of Succession, and Statistical Inference.
- Journal of the American Statistical Association 1927;22(158):209-12.
- 525 20. Jia S, Zhang N, Liu D, et al. Comparative Analysis of the Efficacy of
- 526 Low-Intensity Single-Wavelength Red Light Instrument and Acupuncture Therapy for
- 527 Preventing and Controlling Myopia in Adolescent Children. Advances in Clinical
- 528 Medicine 2022;12(12).
- 529 21. Jin X. Observation of the efficacy of repeated low-intensity red light irradiation
- 530 on the prevention and control of myopia in children and adolescents. Chinese Science
- and Technology Journal Database Medicine 2023(7).
- 532 22. Lai W, Jia Y, Zhang Y, et al. Efficacy of low□ level red light in young children
- with high myopia. Recent Advances in Ophthalmology 2022;42(09):727-30.
- 534 23. Li E, Wang J, Huang H, et al. Efficacy of low-intensity red light on controlling
- the refractive growth of myopia in adolescents. Chinese Science and Technology
- 536 Journals Database Medicine and Health 2022(10).
- 537 24. Ma G, Yan S, Zhao G, Wang K. Comparison of the effects of repeated

- low-intensity red light irradiation and 0.01% atropine eye drops on the prevention and
- 539 control of myopia in children and adolescents. Chinese Journal of Eye Trauma and
- 540 Occupational Ophthalmology 2023;45(8).
- 541 25. Qiu K, Zhou L. Myopic Axial Length Change with Low-Intensity Laser Light
- 542 Therapy. Glass Enamel & Ophthalmic Optics 2021;49(09):17-22.
- 543 26. Wang W, Jiang Y, Zhu Z, et al. Axial Shortening in Myopic Children after
- 544 Repeated Low-Level Red-Light Therapy: Post Hoc Analysis of a Randomized Trial.
- 545 Ophthalmol Ther 2023;12(2):1223-37.
- 546 27. Xiong F, Mao T, Liao H, et al. Orthokeratology and Low-Intensity Laser Therapy
- 547 for Slowing the Progression of Myopia in Children. Biomed Res Int
- 548 2021;2021:8915867.
- 549 28. Xuan M, Zhu Z, Jiang Y, et al. Longitudinal Changes in Choroidal Structure
- 550 Following Repeated Low-Level Red-Light Therapy for Myopia Control: Secondary
- 551 Analysis of a Randomized Controlled Trial. Asia Pac J Ophthalmol (Phila)
- 552 2023;12(4):377-83.
- 553 29. Yang W, Lin F, Li M, et al. Immediate Effect in the Retina and Choroid after 650
- nm Low-Level Red Light Therapy in Children. Ophthalmic Res 2023;66(1):312-8.
- 555 30. Zhou L, Qiu K, Tong L. The Analysis of Clinical Trial of Slowing the Progression
- of Myopiain Children with Low Red Laser. Glass Enamel & Ophthalmic Optics
- 557 2022;50(1).
- 558 31. Zhou L, Xing C, Qiang W, et al. Low-intensity, long-wavelength red light slows
- the progression of myopia in children: an Eastern China-based cohort. Ophthalmic
- 560 Physiol Opt 2022;42(2):335-44.
- 561 32. Zhu X. Analysis of the therapeutic effect of low energy red light on myopia in
- children and adolescents. Chinese Science and Technology Journal Database
- 563 Medicine 2023(7).
- 33. Yan Y, Xue W, Zhao Y, et al. Effect of 650 nm semiconductor laser on juvenile
  myopia control. Journal of Clinical Ophthalmology 2021;29(02):132-7.
- 566 34. Chen Y, Xiong R, Chen X, et al. Efficacy Comparison of Repeated Low-Level
- 567 Red Light and Low-Dose Atropine for Myopia Control: A Randomized Controlled

- 568 Trial. Transl Vis Sci Technol 2022;11(10):33.
- 569 35. Chen H, Wang W, Liao Y, et al. Low-intensity red-light therapy in slowing
- 570 myopic progression and the rebound effect after its cessation in Chinese children: a
- 571 randomized controlled trial. Graefe's Archive for Clinical and Experimental
- 572 Ophthalmology 2023;261(2):575-84.
- 573 36. Tian L, Cao K, Ma DL, et al. Investigation of the Efficacy and Safety of 650 nm
- 574 Low-Level Red Light for Myopia Control in Children: A Randomized Controlled
- 575 Trial. Ophthalmol Ther 2022;11(6):2259-70.
- 576 37. Zhou L, Tong L, Li Y, et al. Photobiomodulation therapy retarded axial length
- 577 growth in children with myopia: evidence from a 12-month randomized controlled
- 578 trial evidence. Sci Rep 2023;13(1):3321.
- 579 38. Zhou W, Liao Y, Wang W, et al. Efficacy of Different Powers of Low-Level Red
- Light in Children for Myopia Control. Ophthalmology 2024;131(1):48-57.
- 39. Tian L, Cao K, Ma DL, et al. Six-month repeated irradiation of 650 nm low-level
- red light reduces the risk of myopia in children: a randomized controlled trial. Int
- 583 Ophthalmol 2023;43(10):3549-58.
- 40. Liu Z, Sun Z, Du B, et al. The Effects of Repeated Low-Level Red-Light Therapy
- on the Structure and Vasculature of the Choroid and Retina in Children with
- 586 Premyopia. Ophthalmol Ther 2024;13(3):739-59.
- 41. Lin ZH, Tao ZY, Kang ZF, Deng HW. A Study on the Effectiveness of 650-nm
- 588Red-Light Feeding Instruments in the Control of Myopia. Ophthalmic Research
- 589 2023;66(1):664-71.
- 590 42. Zhao C, Ni Y, Zeng J. Effect of red-light therapy on retinal and choroidal blood
- 591 perfusion in myopic children. Ophthalmic Physiol Opt 2023;43(6):1427-37.
- 43. Xiong Y, Hu J, Gu C, Tang J. Influence of low 🗆 intensity red light therapy on
- 593 diopter changes , axial length and tear film rupture time in adolescent myopia patients.
- Journal of North Sichuan Medical College 2024;39(01):100-3.
- 595 44. Zhang L, Guo Y, Chen J, et al. Clinical effect of 650-nm low-level red light in
- 596 conjunction with orthokeratology in myopia control. Journal of Otolaryngology and

- 597 Ophthalmology of Shandong University 2024:1-8.
- 598 45. Liu L, Wang Y, Liu F, et al. Effects of repeated low-level red-light therapy on
- 599 macular retinal thickness and microvascular system in children with myopia.
- 600 Photodiagnosis Photodyn Ther 2024;45:103938.
- 46. Wang W, Jiang Y, Zhu Z, et al. Clinically Significant Axial Shortening in Myopic
- 602 Children After Repeated Low-Level Red Light Therapy: A Retrospective Multicenter
- 603 Analysis. Ophthalmol Ther 2023;12(2):999-1011.
- 47. Liu H, Yang Y, Guo J, et al. Retinal Damage After Repeated Low-level Red-Light
- Laser Exposure. JAMA Ophthalmology 2023.
- 48. Tian Y, Xiao Z. Recovery of retinal structural damage after repeated low-intensity
- red light therapy for high myopia: a case report. Chinese Journal of Experimental
- 608 Ophthalmology 2023;41(9):853-5.
- 49. Gwiazda J, Hyman L, Hussein M, et al. A randomized clinical trial of progressive
- addition lenses versus single vision lenses on the progression of myopia in children.
- 611 Invest Ophthalmol Vis Sci 2003;44(4):1492-500.
- 50. Cheng D, Schmid KL, Woo GC, Drobe B. Randomized Trial of Effect of Bifocal
- and Prismatic Bifocal Spectacles on Myopic Progression Two-Year Results. Arch
- 614 Ophthalmol 2010 128(1):12-9.
- 51. Sankaridurg P, Donovan L, Varnas S, et al. Spectacle lenses designed to reduce
- 616 progression of myopia: 12-month results. Optom Vis Sci 2010;87(9):631-41.
- 617 52. Correction of Myopia Evaluation Trial 2 Study Group for the Pediatric Eye
- 618 Disease Investigator G. Progressive-addition lenses versus single-vision lenses for
- slowing progression of myopia in children with high accommodative lag and near
- esophoria. Invest Ophthalmol Vis Sci 2011;52(5):2749-57.
- 621 53. Hasebe S, Jun J, Varnas S. Myopia Control with Positively-Aspherized
- 622 Progressive 2 Addition Lenses- A Two-year, Multicenter, Randomized,
- 623 Controlled Trial. Invest Ophthalmol Vis Sci 2014
- 54. Kanda H, Oshika T, Hiraoka T, et al. Effect of spectacle lenses designed to reduce
- relative peripheral hyperopia on myopia progression in Japanese children: a 2-year
- 626 multicenter randomized controlled trial. Jpn J Ophthalmol 2018;62(5):537-43.

- 55. Lam CSY, Tang WC, Tse DY, et al. Defocus Incorporated Multiple Segments
- 628 (DIMS) spectacle lenses slow myopia progression: a 2-year randomised clinical trial.
- 629 Br J Ophthalmol 2020;104(3):363-8.
- 630 56. Bao J, Yang A, Huang Y, et al. One-year myopia control efficacy of spectacle
- lenses with aspherical lenslets. Br J Ophthalmol 2022;106(8):1171-6.
- 632 57. Bao J, Huang Y, Li X, et al. Spectacle Lenses With Aspherical Lenslets for
- 633 Myopia Control vs Single-Vision Spectacle Lenses: A Randomized Clinical Trial.
- 634 JAMA Ophthalmol 2022;140(5):472-8.
- 58. Liu X, Wang P, Xie Z, et al. One-year myopia control efficacy of cylindrical
- annular refractive element spectacle lenses. Acta Ophthalmol 2023;101(6):651-7.
- 637 59. Rappon J, Chung C, Young G, et al. Control of myopia using diffusion optics
- 638 spectacle lenses: 12-month results of a randomised controlled, efficacy and safety
- 639 study (CYPRESS). Br J Ophthalmol 2023;107(11):1709-15.
- 640 60. Yen M, Liu J, Kao S, Shiao C. Comparison of the effect of atropine and
- 641 cyclopentolate on myopia. Ann Ophthalmol 1989;21(5):180-7.
- 642 61. Shih YF, Chen CH, Chou AC, et al. Effects of different concentrations of atropine
- on controlling myopia in myopic children. JOURNAL OF OCULAR
- 644 PHARMACOLOGY AND THERAPEUTICS 1999;15(1):85-90.
- 645 62. Chua WH, Balakrishnan V, Chan YH, et al. Atropine for the treatment of
- 646 childhood myopia. Ophthalmology 2006;113(12):2285-91.
- 647 63. Chia A, Chua WH, Cheung YB, et al. Atropine for the treatment of childhood
- myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (Atropine for the
- <sup>649</sup> Treatment of Myopia 2). Ophthalmology 2012;119(2):347-54.
- 650 64. Yi S, Huang Y, Yu S, et al. Therapeutic effect of atropine 1% in children with low
- 651 myopia. J AAPOS 2016;20(4):379.
- 652 65. Wang YR, Bian HL, Wang Q. Atropine 0.5% eyedrops for the treatment of
- children with low myopia: A randomized controlled trial. Medicine (Baltimore)
- 654 2017;96(27):e7371.
- 655 66. Yam JC, Jiang Y, Tang SM, et al. Low-Concentration Atropine for Myopia
- 656 Progression (LAMP) Study: A Randomized, Double-Blinded, Placebo-Controlled

- Trial of 0.05%, 0.025%, and 0.01% Atropine Eye Drops in Myopia Control.
- 658 Ophthalmology 2019;126(1):113-24.
- 659 67. Wei S, Li SM, An W, et al. Safety and Efficacy of Low-Dose Atropine Eyedrops
- 660 for the Treatment of Myopia Progression in Chinese Children: A Randomized Clinical
- 661 Trial. JAMA Ophthalmol 2020;138(11):1178-84.
- 662 68. Yam JC, Li FF, Zhang X, et al. Two-Year Clinical Trial of the Low-Concentration
- 663 Atropine for Myopia Progression (LAMP) Study: Phase 2 Report. Ophthalmology
- 664 2020;127(7):910-9.
- 665 69. Cui C, Li X, Lyu Y, et al. Safety and efficacy of 0.02% and 0.01% atropine on
- 666 controlling myopia progression: a 2-year clinical trial. Sci Rep 2021;11(1):22267.
- 667 70. Hieda O, Hiraoka T, Fujikado T, et al. Efficacy and safety of 0.01% atropine for
- 668 prevention of childhood myopia in a 2-year randomized placebo-controlled study. Jpn
- 669 J Ophthalmol 2021;65(3):315-25.
- 670 71. Saxena R, Dhiman R, Gupta V, et al. Atropine for the Treatment of Childhood
- 671 Myopia in India: Multicentric Randomized Trial. Ophthalmology
- 672 2021;128(9):1367-9.
- 673 72. Lee SS, Lingham G, Blaszkowska M, et al. Low-concentration atropine eyedrops
- 674 for myopia control in a multi-racial cohort of Australian children: A randomised
- clinical trial. Clin Exp Ophthalmol 2022;50(9):1001-12.
- 676 73. Yam JC, Zhang XJ, Zhang Y, et al. Three-Year Clinical Trial of
- 677 Low-Concentration Atropine for Myopia Progression (LAMP) Study: Continued
- Versus Washout: Phase 3 Report. Ophthalmology 2022;129(3):308-21.
- 679 74. Chia A, Ngo C, Choudry N, et al. Atropine Ophthalmic Solution to Reduce
- 680 Myopia Progression in Pediatric Subjects: The Randomized, Double-Blind
- Multicenter Phase II APPLE Study. Asia Pac J Ophthalmol (Phila) 2023;12(4):370-6.
- 682 75.Hansen NC, Hvid-Hansen A, Moller F, et al. Safety and efficacy of 0.01% and 0.1%
- low-dose atropine eye drop regimens for reduction of myopia progression in Danish
- 684 children: a randomized clinical trial examining one-year effect and safety. BMC
- 685 Ophthalmol 2023;23(1):438.
- 686 76. Moriche-Carretero M, Revilla-Amores R, Gutierrez-Blanco A, et al. Five-year

- results of atropine 0.01% efficacy in the myopia control in a European population. Br
- 688 J Ophthalmol 2023.
- 689 77. Xu S, Li Z, Zhao W, et al. Effect of atropine, orthokeratology and combined
- 690 treatments for myopia control: a 2-year stratified randomised clinical trial. Br J
- 691 Ophthalmol 2023;107(12):1812-7.
- 692 78. Yam JC, Zhang XJ, Zhang Y, et al. Effect of Low-Concentration Atropine
- 693 Eyedrops vs Placebo on Myopia Incidence in Children: The LAMP2 Randomized
- 694 Clinical Trial. JAMA 2023;329(6):472-81.
- 695 79. Cho P, Cheung SW. Retardation of myopia in Orthokeratology (ROMIO) study: a
- 696 2-year randomized clinical trial. Invest Ophthalmol Vis Sci 2012;53(11):7077-85.
- 697 80. Charm J, Cho P. High Myopia–Partial Reduction Ortho-k A 2-Year Randomized
- 698 Study. Optom Vis Sci 2013.
- 81. Kinoshita N, Konno Y, Hamada N, et al. Efficacy of combined orthokeratology
- and 0.01% atropine solution for slowing axial elongation in children with myopia: a
- 701 2-year randomised trial. Sci Rep 2020;10(1):12750.
- 702 82. Tan Q, Ng AL, Choy BN, et al. One-year results of 0.01% atropine with
- orthokeratology (AOK) study: a randomised clinical trial. Ophthalmic Physiol Opt
  2020;40(5):557-66.
- 83. Guo B, Cheung SW, Kojima R, Cho P. One-year results of the Variation of
- 706 Orthokeratology Lens Treatment Zone (VOLTZ) Study: a prospective randomised
- clinical trial. Ophthalmic Physiol Opt 2021;41(4):702-14.
- 708 84. Jakobsen TM, Moller F. Control of myopia using orthokeratology lenses in
- Scandinavian children aged 6 to 12 years. Eighteen-month data from the Danish
- 710 Randomized Study: Clinical study Of Near-sightedness; TReatment with
- 711 Orthokeratology Lenses (CONTROL study). Acta Ophthalmol 2022;100(2):175-82.
- 712 85. Walline JJ, Jones L, Mutti DO, Zadnik K. A randomized trial of the effects of
- rigid contact lenses on myopia progression. Arch Ophthalmol 2004
- 86. Cheng X, Xu J, Chehab K, et al. Soft Contact Lenses with Positive Spherical
- Aberration for Myopia Control. Optom Vis Sci 2016;93(4):353-66.
- 716 87. Chamberlain P, Peixoto-de-Matos SC, Logan NS, et al. A 3-year Randomized

- 717 Clinical Trial of MiSight Lenses for Myopia Control. Optom Vis Sci
- 718 2019;96(8):556-67.
- 88. Walline JJ, Walker MK, Mutti DO, et al. Effect of High Add Power, Medium Add
- 720 Power, or Single-Vision Contact Lenses on Myopia Progression in Children: The
- 721 BLINK Randomized Clinical Trial. JAMA 2020;324(6):571-80.
- 722 89. Garcia-Del Valle AM, Blazquez V, Gros-Otero J, et al. Efficacy and safety of a
- soft contact lens to control myopia progression. Clin Exp Optom 2021;104(1):14-21.
- 90. Gaume Giannoni A, Robich M, Berntsen DA, et al. Ocular and Nonocular
- Adverse Events during 3 Years of Soft Contact Lens Wear in Children. Optom Vis Sci
- 726 2022;99(6):505-12.
- 91. Shimojo S, Kamitani Y, Nishida S. Afterimage of perceptually filled-in surface.
- 728 Science 2001;293(5535):1677-80.
- 729 92. Expert workgroup of expert consensus on repeated low-level red-light as an
- alternative treatment for childhood myopia. Expert consensus on repeated low-level
- red-light as an alternative treatment for childhood myopia (2022). Chinese Journal of
- Experimental Ophthalmology 2022;40(7):599-603.
- 733 93. Stapleton F, Keay L, Edwards K, et al. The incidence of contact lens-related
- microbial keratitis in Australia. Ophthalmology 2008;115(10):1655-62.
- 735 94. Cheng X, Brennan NA, Toubouti Y, Greenaway NL. Safety of soft contact lenses
- in children: retrospective review of six randomized controlled trials of myopia control.
- 737 Acta Ophthalmol 2020;98(3):e346-e51.
- 738 95. Stapleton F. Contact lens 🗆 related corneal infection in Australia. Clinical and
- 739 Experimental Optometry 2021;103(4):408-17.
- 740 96. Szczotka-Flynn LB, Shovlin JP, Schnider CM, et al. American Academy of
- 741 Optometry Microbial Keratitis Think Tank. Optom Vis Sci 2021;98(3):182-98.
- 742 97. Bullimore MA, Sinnott LT, Jones-Jordan LA. The risk of microbial keratitis with
- overnight corneal reshaping lenses. Optom Vis Sci 2013;90(9):937-44.
- 744 98. Ha A, Kim SJ, Shim SR, et al. Efficacy and Safety of 8 Atropine Concentrations
- 745 for Myopia Control in Children: A Network Meta-Analysis. Ophthalmology
- 746 2022;129(3):322-33.

- 747 99. Gong Q, Janowski M, Luo M, et al. Efficacy and Adverse Effects of Atropine in
- 748 Childhood Myopia: A Meta-analysis. JAMA Ophthalmol 2017;135(6):624-30.
- 100. Zhang M, Congdon N, Li L, et al. Myopia, spectacle wear, and risk of bicycle
- accidents among rural Chinese secondary school students: the Xichang Pediatric
- 751 Refractive Error Study report no. 7. Arch Ophthalmol 2009;127(6):776-83.
- 752

# 754 Figure Legends

- 755
- **Figure 1.** Study selection outlined according to Preferred Reporting Items for
- 757 Systematic Reviews and Meta-Analyses (PRISMA) guidelines. RCT=randomized
- 758 controlled trial.





- 761 Figure 2. Risk of bias assessment by Cochrane Risk of Bias Tool of the included
- 762 RCTs. RCT=randomized controlled trial.



No. of Patients	Treatment	Age (y)	Female (%)	Mean SER (D)	Mean AL	Completion			
by Study					( <b>mm</b> )	Rate (%)			
(Study Type)									
Jiang et al 2021 (RC	CT) <sup>8</sup>			1					
117	Intervention (RLRL)	8-13	62 (52.1)	-2.49 (0.92)	24.5 (0.67)	98.3			
129	Control (SVS)	8-13	72 (49.7)	-2.67 (1.06)	24.6 (0.86)	89.0			
Yan et al 2021 (RC	T) <sup>33</sup>								
60	Intervention (RLRL)	7-12	59 (49 2)	-2.52 (1.15)	24.2 (0.92)	100			
60	Control (SVS)	7-12	- 58 (48.3)	-2.53 (1.15)	24.4 (0.79)	100			
Xiong et al 2022 (post-trial follow-up study) <sup>9</sup>									
11	RLRL-RLRL	8-13	4 (36.4)	-1.77 (0.57)	24.9 (0.94)	-			
10	SVS-RLRL	8-13	5 (50.0)	-2.57 (1.11)	24.8 (0.71)	-			
52	RLRL-SVS	8-13	26 (50.0)	-2.50 (0.83)	24.5 (0.58)	-			
41	SVS-SVS	8-13	26 (63.4)	-2.76 (1.15)	24.6 (0.94)	-			
Dong et al 2022 (R	CT) <sup>11</sup>					L			
56	Intervention (RLRL)	7-12	30 (53.6)	-3.13 (1.91)	24.7 (1.04)	94.6			
55	Control (Sham device)	7-12	26 (46.4)	-2.82 (1.86)	24.6 (0.96)	98.2			
Chen (a) et al 2022	Chen (a) et al 2022 (RCT) <sup>34</sup>								
30	Intervention (RLRL)	7-15	17 (54.8)	-2.60 (1.17)	24.5 (0.79)	96.8			
30	Control (0.01% atropine)	7-15	14 (45.2)	-2.59 (1.24)	24.7 (0.98)	96.8			

Table 1. Characteristics of included studies.

Chen (b) et al 2022	2 (RCT) <sup>35</sup>								
46	Intervention (RLRL)	6-13	19 (41.3)	-2.54 (1.04)	24.6 (0.97)	90.2			
40	Control (SVS)	6-13	15 (37.5)	-2.29 (0.77)	24.6 (0.76)	78.4			
Tian et al 2022 (RCT) <sup>36</sup>									
91	Intervention (RLRL)	6-12	55 (49.1)	-2.00 (0.33)	24.3 (0.92)	81.3			
88	Control (SVS)	6-12	57 (50.9)	-2.00 (0.25)	24.2 (0.85)	78.6			
He et al 2023 (RCT	( <sup>10</sup>								
126	Intervention (RLRL)	6-11	68 (48.9)	0.14 (0.30)	23.4 (0.68)	90.7			
122	Control (SVS)	6-11	71 (51.1)	0.16 (0.28)	23.3 (0.69)	87.8			
Zhou (a) et al 2023 (RCT) <sup>37</sup>									
20	Intervention (RLRL)	3-16	9 (37.5)	-2.93 (1.87)	24.6 (1.16)	96.0			
15	Control (SVS)	3-16	7 (41.2)	-2.11 (1.21)	24.4 (0.87)	76.0			
Zhou (b) et al 2023	<sup>3</sup> (RCT) <sup>38</sup>								
43	Intervention (RLRL 0.37mW)	6-15	20 (40.0)	-1.72 (0.91)	24.2 (0.79)	86.0			
47	Intervention (RLRL 0.60mW)	6-15	25 (50.0)	-2.01 (0.87)	24.1 (0.88)	94.0			
44	Intervention (RLRL 1.20mW)	6-15	24 (48.0)	-2.08 (1.33)	24.5 (0.91)	88.0			
43	Control (SVS)	6-15	21 (42.0)	-2.10 (0.90)	24.4 (0.90)	86.0			
Tian (a) et al 2023 (RCT) <sup>39</sup>									
56	Intervention (RLRL)	6-12	33 (58.9)	0.25 (0.25)	23.1 (0.80)	100			
56	Control (SVS)	6-12	31 (55.4)	0.25 (0.19)	23.1 (0.70)	100			
Lin et al 2023 (non	-randomized controlled trial) <sup>41</sup>								

41	Intervention (RLRL)	6-18		-3.20 (2.82)	24.3 (1.04)	58.6				
58	Intervention (RLRL)	6-18	84 (51.2)	-7.93 (2.95)	25.7 (1.57)	82.9				
65	Control (SVS)	6-18	-	-2.32 (2.64)	24.3 (1.21)	92.9				
Zhao et al 2023 (non-randomized controlled trial) <sup>42</sup>										
47	Intervention (RLRL)	6-18	18 (38.3)	-2.31 (1.26)	24.6 (0.88)	100				
20	Control (SVS)	6-18	8 (40.0)	-2.75 (0.84)	24.8 (0.90)	100				
Wang et al 2023 (re	trospective study) <sup>46</sup>									
434	Intervention (RLRL)	3-17	200 (46.1)	-3.74 (2.60)	24.9 (1.20)	-				
Liu et al 2023 & Tian (b) et al 2023 (case report) <sup>47,48</sup>										
1	Intervention (RLRL)	12 1 (100)	1 (100)	OD -6.75D						
1			1 (100)	OS -6.25D	-	-				
Liu (a) et al 2024 (I	$RCT)^{40}$									
47	Intervention (RLRL)	7-12	19 (44.2)	0.17 (0.35)	23.6 (0.78)	91.5				
47	Control (SVS)	7-12	20 (47.6)	0.30 (0.35)	23.3 (0.73)	89.4				
Liu (b) et al 2024 (s	ingle-arm study) <sup>45</sup>									
40	Intervention (RLRL)	7-14	17 (42.5)	-2.75 (1.43)	24.9 (0.97)	100				
Xiong et al 2024 (n	Xiong et al 2024 (non-randomized controlled trial) <sup>43</sup>									
45	Intervention (RLRL)	7-16	22 (48.9)	-3.00 (0.90)	23.6 (0.35)	100				
45	Control (SVS)	7-16	23 (51.1)	-3.02 (0.11)	23.6 (0.37)	100				
Zhang et al 2024 (n	on-randomized controlled trial)*44									
44	Intervention (RLRL)	≥7	25 (56.8)	-1.87 (1.16)	24.1 (0.80)	100				

32	Intervention (OK)	≥7	14 (43.8)	-2.44 (1.15)	24.2 (0.73)	100
29	Intervention (RLRL+OK)	≥7	10 (34.5)	-2.55 (1.32)	24.5 (0.96)	100
36	Control (SVS)	≥7	18 (50.0)	-2.11 (1.11)	24.3 (0.82)	100

\* Only eye number for each group and total participant number was available in the publication.

Data were presented as number (percentage) or mean (standard deviation).

RLRL=repeated low-level red-light; SVS=single vision spectacles; RCT=randomized controlled trial; SER= spherical equivalent refraction; AL=axial length; OK=orthokeratology.

Study	Follow-up (mo)	Visual function outcome	Ocular Structural Outcome	Adverse events
Jiang et al 2021 <sup>8</sup>	12	108 (97.3%) participants achieved	No structural damage on	• No adverse events were reported,
		BCVA of 20/20, and the BCVA in	photosensory layer was	including glare, flash blindness, or
		the remaining 3 (2.7%) participants	identified by OCT. (n=72)	afterimages.
		was 20/25. *		• No severe adverse events developed,
				including sudden vision loss by 2 lines
				occurring in a period of a few second/s or
				minutes to a few days or scotoma.
Yan et al 2021 <sup>33</sup>	12	-	-	• No ocular adverse events were reported,
				including conjunctival hyperemia,
				edema, photophobia, tears, corneal
				epithelial damage, lens opacity, macular
				damage.
				• No cognitive impairment and behavioral
				abnormalities were found.
Xiong et al 2022 <sup>9</sup>	12	10 (100%) participants maintained	No structural damage on	• No severe adverse events or side effects
		BCVA of 20/20.	photosensory layer was	including sudden vision loss of more than
			identified by OCT.	two lines, scotoma, dazzling, short-term
				glare, flash blindness, and afterimages
				developed.
Xiong et al 2022 <sup>9</sup>	24	11 (100%) participants maintained	No structural damage on	No severe adverse events or side effects

Table 2. Visual functio	n, ocular structures	s and adverse even	ts reported in RLRL studies.
-------------------------	----------------------	--------------------	------------------------------

		BCVA of 20/20.	photosensory layer was	including sudden vision loss of more than
			identified by OCT.	two lines, scotoma, dazzling, short-term
				glare, flash blindness, and afterimages
				developed.
Dong et al 2022 <sup>11</sup>	6	-	-	18 adverse events were reported in 13
				participants, but none were related to
				RLRL therapy. †
Chen (a) et al	12	58 eyes (100%) maintained BCVA	No structural damage was	• No severe adverse events were reported,
$2022^{34}$		of 20/20.	identified by OCT.	including blindness, death,
				hospitalization, or conditions requiring
				medical or surgical interventions.
				$\cdot$ No adverse events including a sudden
				vision loss of two lines or more, a
				scotoma, photophobia, allergy, dry
				mouth, or tachycardia developed.
				• 1 participant reported dizziness after the
				red-light therapy, but the symptoms
				resolved after a few minutes and only
				occurred in the immediate post-treatment
				period for a few days.
Chen (b) et al	12	BCVA remained normal at each	No structural damage	No adverse events including dazzling,
$2022^{35}$		follow-up visit.	including vitreomacular	glare, long-term afterimages, and flash
			traction, macular schisis,	blindness were reported.

			macular hole, intraretinal	
			fluid, subretinal fluid,	
			hemorrhage, retinal pigment	
			epithelium proliferation, and	
			atrophy was identified by	
			OCT.	
Tian et al 2022 <sup>36</sup>	6	-		No adverse events including photophobia, eye itching, burning sensation, dry eye, blurred vision, glare, dazzling, keratitis, and conjunctivitis were reported.
He et al 2023 <sup>10</sup>	12	123 (100%) participants achieved BCVA of 20/25.	No structural damage including vitreomacular traction, macular schisis, macular hole, intraretinal fluid, subretinal fluid, hemorrhage, retinal pigment epithelium proliferation, and atrophy was identified by OCT.	No adverse event was reported, including glare, flash blindness, or afterimages longer than 6 minutes after treatment. ††
Zhou (a) et al 2023 <sup>37</sup>	12	No BCVA indicated visual function loss.	No structural damage was identified by OCT.	• Reversible subjective symptoms without objective ocular abnormalities (CTCAE grade 1) ‡, including reversible vision

				loss lasting $2.1 \pm 0.7$ min (n=23) after
				red-light therapy due to flash blindness or
				glare with afterimage, and afterimage
				with an average of $3.2 \pm 1.2$ min.
				• No dry eye, cataract, keratitis, night
				blindness, photophobia or any other
				permanent visual impairment.
				• No systemic adverse effects (such as
				headache or dizziness), severe adverse
				events, or other adverse events related to
				grades of ocular diseases: Grade 2-5 of
				CTCAE.
Zhou (b) et al	6	BCVA remained normal at each	No retinal or choroidal	No adverse events were reported.
2023 <sup>38</sup>		follow-up visit.	structural abnormalities were	
			identified by OCT.	
Tian (a) et al 2023 <sup>39</sup>	6	-	-	No adverse events were reported.
Lin et al 2023 <sup>41</sup>	2	-	-	· Afterimage is the most common
				phenomenon post RLRL therapy, which
				can be alleviated by a short period of
				eye-closing and rest; with the progression
				of treatment, this phenomenon does not
				appear to worsen.

				$\cdot$ No adverse events were reported.
Zhao et al 2023 <sup>42</sup>	1	-	No retinal structure related	-
			photodamage was identified	
			by OCT.	
Wang et al 2023 <sup>46</sup>	At least 12	-	-	No adverse events were reported.
Liu et al & Tian	5	Binocular BCVA declined from	• Bilateral foveal ellipsoid	Prolonged afterimages after light therapy
(b) et al 2023 <sup>47,48</sup>		20/20 to 20/30. §	zone disruption and	(occasionally exceeding 8 minutes).
		•Multifocal electroretinogram	interdigitation zone	
		revealed the response of the central	discontinuity were identified	
		macula (ring 1) was moderately	by OCT. §	
		decreased and the response of	• Fundus photographs	
		paramacula (ring 2 and 3) was	revealed bilaterally darkened	
		mildly decreased in both eyes.	foveae with a	
			hypoautofluorescent plaque	
			in autofluorescence images.	
Liu (a) et al	12	No BCVA indicated visual function	No structural damage was	No adverse events were reported.
$2024^{40}$		loss.	identified by OCT.	
Liu (b) et al	6	-	No change in macular	No adverse events were reported.
$2024^{45}$			structure or microcirculatory	
			system was identified by	
			OCT and OCTA.	
Xiong et al $2024^{43}$	6	-	No ocular surface damage	No adverse events were reported.

			was found, and no structural	
			damage or macular	
			hemorrhage was identified by	
			OCT.	
Zhang et al 2024 <sup>44</sup>	6	BCVA remained unchanged at each	No structural damage within	No adverse events were reported.
		follow-up visit compared to	6mm macular region was	
		baseline.	identified by OCT.	

 $RLRL = repeated \ low-level \ red-light \ therapy; \ mo = month; \ BCVA = best \ corrected \ visual \ acuity; \ OCT = optical \ coherence \ tomography.$ 

\*In the SVS control arm, the proportion of compromised BCVA 20/25 was 8 of 112 (7.1%).

†18 adverse events included one case each of influenza, an eyelid injury requiring surgical repair, and acute mesenteric lymphadenitis; two cases each of earwax blockage, and allergic rhinitis; and three cases of dental caries.

††Two participants dropped out due to the afterimage duration exceeded 6 minutes at baseline.

‡Common Terminology Criteria for Adverse Events (CTCAE) grade 1 refers to mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated.

\$After 3 months without RLRL therapy, the bilateral outer retinal damage partially recovered, and the visual acuity improved to 20/25 in both eyes. After 4 months discontinued RLRL therapy, the bilateral outer retinal damage totally recovered.

Table 3. Estimated NNH and NNH/NNT ratios associated with RLRL therapy.

Variable	Multiplier	Value*	
Annual incidence of vision loss		8.77	
Years of vision loss accrued	$\times$ 65 years	570	
NNH†			
For 1 year of vision loss	10,000/years vision loss	17.5	
For 5 years of vision loss	$5 \times 10,000$ /years vision loss	87.7	

\* We assumed that the annual incidence of vision loss from RLRL therapy as 8.77 per 10,000 patient-years. Any vision loss is estimated to be experienced for 65 years after the event.

<sup>†</sup> The NNH/NNT ratios are 12.7-fold for -3D, 14.4-fold for -4D, 16.4-fold for -5D, 18.1-fold for -6D, 19.9-fold for -7D and 21.4-fold for -8D with RLRL therapy.

All values are presented per 10,000 patients.

RLRL=repeated low-level red-light; NNH=number needed to harm; NNT=number needed to treat.

Interventions	Baseline age	Number of	Person- years	Ocular adverse	Ocular adverse events per	95% CI*
	criteria (years)	participants		events	100 patient-years	
RLRL <sup>8-11,33-48</sup>	3-18	1436	1139.8	1	0.088	0.02-0.50
Low-dose atropine <sup>60-78</sup>	4-16	2736	5368	393	7.32	6.65-8.05
Orthokeratology <sup>76,79-84</sup>	6-12	231	364.5	75	20.6	16.7-25.0
Anti-myopia contact lens <sup>85-90</sup>	7-15	697	1899	366	19.3	17.6-21.1
Spectacles designed for myopia reduction <sup>49-59</sup>	6-16	1247	2299	5	0.22	0.09-0.51

Table 4. Comparison of the ocular adverse event incidence rate between RLRL and other interventions.

RLRL=repeated low-level red-light; CI=confidence interval.

Anti-myopia contact lens includes rigid gas permeable contact lens and soft multifocal contact lens. Spectacles designed for myopia reduction includes bifocal lens, progressive addition spectacles, aspherical lenslets and peripheral defocus spectacles.

\*95% CI was calculated using Wilson methods.